Scientific context only. Not medical advice, not a recommendation to use.
At a glance
KPV is the C-terminal tripeptide (lysine-proline-valine) of the hormone α-MSH, corresponding to its positions 11–13. In cell and rodent models an inflammation-modulating activity has been described, primarily via inhibition of the NF-κB signalling pathway. The evidence is drawn almost exclusively from preclinical work (cell culture and mouse); controlled human studies are essentially absent. KPV is not an approved medicinal product.
Researched for
Intestinal inflammation (preclinical colitis models)Inflammation modulationSkin and wound-healing models
Official status
US: Research only
Not approved as a medicinal product. KPV is handled as a research substance; there is no FDA approval for any therapeutic use.
KPV is the C-terminal fragment of α-melanocyte-stimulating hormone (α-MSH). In preclinical models the inflammation-modulating activity is attributed predominantly to inhibition of the NF-κB and MAP-kinase signalling pathways, accompanied by reduced release of pro-inflammatory mediators. Cellular uptake via the peptide transporter PepT1 has also been described. The precise molecular mechanisms are not conclusively understood and not confirmed in humans.
02
Evidence at a glance
Reading note. The distribution shows on which evidence tier each observation sits. Strong colours mark stronger evidence — weaker tiers are deliberately visible, not hidden.
Inhibition of NF-κB and MAP-kinase signalling in intestinal epithelial and immune cells
What does NOT follow: In-vitro observation in cell lines — does not predict an effect in a living organism or in humans.
Animal model
Maus (DSS- und TNBS-Colitis)
Dalmasso G et al. 2008
Reduced intestinal inflammation in chemically induced colitis models
What does NOT follow: Observed in animal models — not confirmed in humans. Model colitis reflects human inflammatory bowel disease only to a limited degree.
Preclinical
Zell- und Mausmodelle
Dalmasso G et al. 2008
Uptake via the peptide transporter PepT1 as a possible entry route into target cells
What does NOT follow: Mechanistic finding from preclinical systems; relevance to humans is not established.
Animal model
Maus (Ulcerative-Colitis-Modell)
Xiao B et al. 2017
Accelerated mucosal healing with targeted oral nanoparticle delivery
What does NOT follow: Animal model with an experimental carrier system; not transferable to humans and no application can be derived.
Theoretical
—
Clinical benefit in humans (e.g. in inflammatory bowel disease or skin conditions)
What does NOT follow: No controlled human studies available. Statements about human benefit are hypothetical.
05
Pharmacokinetics
No robust pharmacokinetic human data available. A model curve is not invented.
06d
Safer use & risks
Risk notes for harm reduction — descriptive, not a usage or dosing guide.
⚠ Important — please read
This platform does NOT provide usage or dosing instructions. The points below describe risks and are meant to help avoid harm — they do not replace medical advice. Anyone who uses a substance should discuss it with a doctor.
There is no approved human use for this substance. What circulates online about amounts and frequency is self-experimentation without a safety net.
Online numbers are not a benchmark
Amounts from TikTok, YouTube and forums are mostly imitation rather than data — and are often wrongly derived from animal studies (µg/kg). Not a reliable benchmark for humans.
Sterility & infection risk
Injection solutions prepared or stored non-sterile carry an infection and abscess risk. Contamination is common with grey-market product.
Unknown product quality
Research-/grey-market product is not quality-tested: identity, purity and actual content are often unknown, and counterfeits occur.
Mind interactions
Combinations with medications or pre-existing conditions can carry risks (see the Interactions section). Clarify with a doctor beforehand.
Warning signs — seek medical help
With persistent pain, redness/swelling at the injection site, fever, shortness of breath, racing heart, chest pain or allergic reactions, seek medical help immediately.
A doctor, not a forum
Concrete questions about use and amount belong in a conversation with a doctor — not in a comment thread.
07b
Interactions & combinations
Documented interactions and contraindications from studies, prescribing information and guidelines. Where no data exists, this is stated.
Reporting of risks, NOT a combination guide. The absence of an entry does not mean „safe to combine“ but „not sufficiently studied“.
No documented interactions recorded
We have not yet found robustly documented interactions for this peptide. This does NOT mean none exist — the data is limited.
10
Anecdotal observations
Weakest evidence tier — not supported by studies
Reading note. This section gathers popular claims from communities and forums. They are explicitly marked as weakest-tier evidence. Unblinded self-reports are particularly prone to placebo, recall and confirmation biases.
Why no amounts or protocols are listed here. We deliberately show only WHAT communities report — not in what amount or how it is used. Anecdotal "doses" or "biohacker protocols" are neither verified nor standardised nor safe; publishing them would be a usage guide, which we do not provide on principle. Specific amounts belong in a conversation with a doctor, not in a forum.
KPV (an alpha-MSH fragment) is described in biohacking circles mainly for gut inflammation, irritable bowel and inflammatory skin conditions.
recurring in gut/skin forums
Not supported by studies: The evidence is almost entirely preclinical (cell culture and animal models of inflammation); controlled human studies are absent. With grey-market sourcing the purity is unverified.
11
Legal status by country
Country
Status
Note
Checked
United States
Research only
Not approved as a medicinal product. KPV is handled as a research substance; there is no FDA approval for any therapeutic use.
2026-06-07
Germany
Unapproved
Not approved as a medicinal product; German drug and advertising law (AMG, HWG) apply. No authorisation for medical use.
2026-06-07
12
Reconstitution calculator
Pure mg/mL maths — works like a calculator. Not a usage recommendation.
Peptides ship as a dry powder. Once dissolved in a liquid (reconstitution), this calculator answers a single question: how much substance is in one millilitre of solution afterwards?
1Enter the vial's substance amount (printed on the label).
2Enter how much solvent you add.
3Result = concentration in mg per mL.
Printed on the label
/
Liquid you add
=
2.50
mg / mL
5 mg in 2 mL gives 2.50 mg/mL — each millilitre contains 2.50 mg of substance.
Critical role of PepT1 in promoting colitis-associated cancer and therapeutic benefits of the anti-inflammatory PepT1-mediated tripeptide KPV in a murine model
Findings:PepT1 is discussed as a possible therapeutic target; KPV showed anti-inflammatory effects in the model.
Limitations:Animal model; mechanistic conclusions are not readily transferable to humans.